Ardelyx Inc
Biotechnology
Ardelyx Inc (ARDX) Stock News
The latest ARDX headlines and market coverage — 10 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.
- GlobeNewswire Inc.·
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Baidu, Inc. (BIDU), Ardelyx, Inc. (ARDX), and Better Home & Finance Holding Company (BETR) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against Baidu, Ardelyx, and Better Home & Finance Holding Company. The lawsuits allege materially false and misleading statements regarding business operations and financial projections. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.
- GlobeNewswire Inc.·
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm is notifying investors in Ardelyx, Inc. who purchased stock between January 13, 2025 and August 6, 2026 about a securities class action lawsuit. The complaint alleges that Ardelyx made materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access. Investors have until November 16, 2026 to serve as lead plaintiff.
- GlobeNewswire Inc.·
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA.
- GlobeNewswire Inc.·
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's commercial performance and growth prospects for drugs XPHOZAH and IBSRELA, while concealing information about payer-related access barriers, prior authorization requirements, and step edit requirements that hindered patient access and new-patient starts. The deadline to serve as lead plaintiff is November 16, 2026.
- GlobeNewswire Inc.·
ARDX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Securities Class Action Lawsuit
Robbins LLP reminds investors of the November 16, 2026 lead plaintiff deadline in a securities class action against Ardelyx, Inc. (ARDX). The lawsuit alleges the company misled investors about commercial performance and growth prospects for its drugs ISBRELA and XPHOZAH, concealing material adverse facts about payer access barriers and reimbursement challenges. On August 6, 2026, Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.
- GlobeNewswire Inc.·
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations under the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers that impacted patient access to its drugs XPHOZAH and IBSRELA, causing delays in new-patient starts and prescription fulfillment. The class period runs from January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.
- GlobeNewswire Inc.·
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that Ardelyx provided materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access and prescription fulfillment. Investors who wish to serve as lead plaintiff must file by November 16, 2026.
- GlobeNewswire Inc.·
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. (ARDX)
A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.
- GlobeNewswire Inc.·
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Faruqi & Faruqi, LLP is investigating securities fraud claims against Ardelyx (NASDAQ: ARDX) for allegedly misleading investors about commercial performance of drugs XPHOZAH and IBSRELA and failing to disclose payer access barriers. The company reduced 2026 IBSRELA revenue guidance and withdrew XPHOZAH long-term guidance on August 6, 2026, causing stock to drop 18% in one day. Investors who purchased securities between January 13, 2025 and August 6, 2026 may be eligible to participate in the class action with a November 16, 2026 deadline to seek lead plaintiff status.